Antiproliferative effect of YM881 (SMANCS) on glioma cells in vitro.
Growth inhibitory activity of YM881 (SMANCS) against 3 human cultured cell lines and one rat cultured cell line derived from glioma cells was assessed quantitatively. YM881 showed potent cytotoxicity against all glioma cell lines tested; the IC50 of this drug was 1.9-8.4 micrograms/ml. YM881 may be classified as a concentration-dependent drug but it has also a time-dependent effect. Flow cytometric studies of the DNA histogram showed accumulation in the G2-M phase with YM881. These findings suggest that YM881 may be useful in the treatment of glioma.
Kuratsu
J
J
Department of Neurosurgery, Kumamoto University Medical School, Japan.
Takaki
S
S
Kochi
M
M
Mihara
Y
Y
Ushio
Y
Y
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D004354:Drug Screening Assays, Antitumor; D005434:Flow Cytometry; D005910:Glioma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008299:Maleic Anhydrides / Q000494:pharmacology*; D011137:Polystyrenes / Q000494:pharmacology*; D051381:Rats; D014407:Tumor Cells, Cultured; D009353:Zinostatin / Q000031:analogs & derivatives* / Q000494:pharmacology
D008299:Maleic Anhydrides; D011137:Polystyrenes; C035755:poly(maleic acid-styrene)neocarzinostatin; D009353:Zinostatin